|
1
|
Rosenfield PJ, Martidis A and Tennant M:
Age-related macular degeneration. In: Ophthalmology: Expert
Consult. 3rd edition. Yanoff M, Duker JS and Augsburger JJ (eds).
Elsevier Mosby, Philadelphia, PA, 2009.
|
|
2
|
Cheung LK and Eaton A: Age-related macular
degeneration. Pharmacotherapy. 33:838–855. 2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Villegas VM, Aranguren LA, Kovach JL,
Schwartz SG and Flynn HW Jr: Current advances in the treatment of
neovascular age-related macular degeneration. Expert Opin Drug
Deliv. 14:273–282. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Chakravarthy U, Harding SP, Rogers CA,
Downes SM, Lotery AJ, Culliford LA and Reeves BC: IVAN study
investigators. Alternative treatments to inhibit VEGF in
age-related choroidal neovascularisation: 2-year findings of the
IVAN randomised controlled trial. Lancet. 382:1258–1267.
2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Martin DF, Maguire MG, Fine SL, Ying GS,
Jaffe GJ, Grunwald JE, Toth C, Redford M and Ferris FL III:
Comparison of Age-related Macular Degeneration Treatments Trials
(CATT) Research Group. Ranibizumab and bevacizumab for treatment of
neovascular age-related macular degeneration: Two-year results.
Ophthalmology. 119:1388–1398. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Schauwvlieghe AM, Dijkman G, Hooymans JM,
Verbraak FD, Hoyng CB, Dijkgraaf MG, Peto T, Vingerling JR and
Schlingemann RO: Comparing the effectiveness of bevacizumab to
ranibizumab in patients with exudative age-related macular
degeneration. The BRAMD Study. PLoS One.
11(e0153052)2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Krebs I, Schmetterer L, Boltz A, Told R,
Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei
S and Binder S: MANTA Research Group. A randomised double-masked
trial comparing the visual outcome after treatment with ranibizumab
or bevacizumab in patients with neovascular age-related macular
degeneration. Br J Ophthalmol. 97:266–271. 2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kodjikian L, Souied EH, Mimoun G,
Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L and Aulagner G:
GEFAL Study Group. Ranibizumab versus Bevacizumab for neovascular
age-related macular degeneration: Results from the GEFAL
noninferiority randomized trial. Ophthalmology. 120:2300–2309.
2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Berg K, Pedersen TR, Sandvik L and
Bragadóttir R: Comparison of ranibizumab and bevacizumab for
neovascular age-related macular degeneration according to LUCAS
treat-and-extend protocol. Ophthalmology. 122:146–152.
2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bro T, Derebecka M, Jørstad ØK and
Grzybowski A: Off-label use of bevacizumab for wet age-related
macular degeneration in Europe. Graefes Arch Clin Exp Ophthalmol.
258:503–511. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
American Society of Retina Specialists:
Preferences and trends Survey 2018. urihttps://www.asrs.org/content/documents/2018-global-trends-in-retina-survey-highlights-website.pdfsimplehttps://www.asrs.org/content/documents/2018-global-trends-in-retina-survey-highlights-website.pdf.
Accessed May 1, 2020.
|
|
12
|
Elshout M, Webers CAB, van der Reis MI and
Schouten JSAG: A systematic review on the quality, validity and
usefulness of current cost-effectiveness studies for treatments of
neovascular age-related macular degeneration. Acta Ophthalmol.
96:770–778. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Low A, Faridi A, Bhavsar KV, Cockerham GC,
Freeman M, Fu R, Paynter R, Kondo K and Kansagara D: Comparative
effectiveness and harms of intravitreal antivascular endothelial
growth factor agents for three retinal conditions: A systematic
review and meta-analysis. Br J Ophthalmol. 103:442–451.
2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Stanca HT, Stanca S, Tabacaru B, Boruga M
and Balta F: Bevacizumab in Wet AMD treatment: A tribute to the
thirteen years of experience from the beginning of the anti-VEGF
era in Romania. Exp Ther Med. 18:4993–5000. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Brănisteanu DC, Munteanu M, Branisteanu
DE, Stanca HT, Moraru A and Baltă F: ‘Off-Label’ drug use - ethical
challenges. Case study - AVASTIN®. Rev Rom Bioet.
13(170)2015.
|
|
16
|
Solomon SD, Jefferys JL, Hawkins BS and
Bressler NM: Submacular Surgery Trials Research Group. Incident
choroidal neovascularization in fellow eyes of patients with
unilateral subfoveal choroidal neovascularization secondary to
age-related macular degeneration: SST report No. 20 from the
Submacular Surgery Trials Research Group. Arch Ophthalmol.
125:1323–1330. 2007.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Barbazetto IA, Saroj N, Shapiro H, Wong P,
Ho AC and Freund KB: Incidence of new choroidal neovascularization
in fellow eyes of patients treated in the MARINA and ANCHOR trials.
Am J Ophthalmol. 149:939–946.e1. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Parikh R, Avery RL, Saroj N, Thompson D
and Freund KB: Incidence of new choroidal neovascularization in
fellow eyes of patients with age-related macular degeneration
treated with intravitreal aflibercept or ranibizumab. JAMA
Ophthalmol. 137:914–920. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Fasler K, Fu DJ, Moraes G, Wagner S,
Gokhale E, Kortuem K, Chopra R, Faes L, Preston G, Pontikos N, et
al: Moorfields AMD database report 2: Fellow eye involvement with
neovascular age-related macular degeneration. Br J Ophthalmol.
104:684–690. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Rasmussen A, Fuchs J, Hansen LH, Larsen M,
Sander B and Lund-Andersen H: Neovascular age-related macular
degeneration: Is it worthwhile treating an eye with poor visual
acuity, if the visual acuity of the fellow eye is good? Eye (Lond).
31:978–980. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
de Oliveira Dias JR, Zhang Q, Garcia JMB,
Zheng F, Motulsky EH, Roisman L, Miller A, Chen CL, Kubach S, de
Sisternes L, et al: Natural history of subclinical
neovascularization in nonexudative age-related macular degeneration
using swept-source OCT angiography. Ophthalmology. 125:255–266.
2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Yanagi Y, Mohla A, Lee SY, Mathur R, Chan
CM, Yeo I, Wong TY and Cheung CMG: Incidence of fellow eye
involvement in patients with unilateral exudative age-related
macular degeneration. JAMA Ophthalmol. 136:905–911. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Maguire MG, Daniel E, Shah AR, Grunwald
JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin
AA, et al: Comparison of Age-Related Macular Degeneration
Treatments Trials (CATT Research Group): Incidence of choroidal
neovascularization in the fellow eye in the comparison of
age-related macular degeneration treatments trials. Ophthalmology.
120:2035–2041. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zehetner C, Kirchmair R, Huber S,
Kralinger MT and Kieselbach GF: Plasma levels of vascular
endothelial growth factor before and after intravitreal injection
of bevacizumab, ranibizumab and pegaptanib in patients with
age-related macular degeneration, and in patients with diabetic
macular oedema. Br J Ophthalmol. 97:454–459. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chakravarthy U, Harding SP, Rogers CA,
Downes SM, Lotery AJ, Wordsworth S and Reeves BC: IVAN Study
Investigators. Ranibizumab versus bevacizumab to treat neovascular
age-related macular degeneration: One-year findings from the IVAN
randomized trial. Ophthalmology. 119:1399–1411. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Avery RL, Castellarin AA, Steinle NC,
Dhoot DS, Pieramici DJ, See R, Couvillion S, Nasir MA, Rabena MD,
Le K, et al: Systemic pharmacokinetics following intravitreal
injections of ranibizumab, bevacizumab or aflibercept in patients
with neovascular AMD. Br J Ophthalmol. 98:1636–1641.
2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
García-Quintanilla L, Luaces-Rodríguez A,
Gil-Martínez M, Mondelo-García C, Maroñas O, Mangas-Sanjuan V,
González- Barcia M, Zarra-Ferro I, Aguiar P, Otero-Espinar FJ and
Fernández-Ferreiro A: Pharmacokinetics of intravitreal anti-VEGF
drugs in age-related macular degeneration. Pharmaceutics.
11(365)2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Avery RL, Pearlman J, Pieramici DJ, Rabena
MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R and Patel A:
Intravitreal bevacizumab (Avastin) in the treatment of
proliferative diabetic retinopathy. Ophthalmology.
113:1695.e1–1695.e15. 2006.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Bakbak B, Ozturk BT, Gonul S, Yilmaz M and
Gedik S: Comparison of the effect of unilateral intravitreal
bevacizumab and ranibizumab injection on diabetic macular edema of
the fellow eye. J Ocul Pharmacol Ther. 29:728–732. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Karaca C, Oner AO, Mirza E, Polat OA and
Sahiner M: Bilateral effect of unilateral bevacizumab injection in
retinopathy of prematurity. JAMA Ophthalmol. 131:1099–1101.
2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Malbin B, Patel HP, He Y, Le K and Lin X:
Comparative eye effect of unilateral intravitreal bevacizumab,
ranibizumab, and aflibercept for diabetic macular edema. J
Vitreoretin Dis. 3:86–89. 2019.
|
|
32
|
Isildak H, Schwartz SG and Flynn HW Jr:
Therapeutic effect of anti-VEGF for age-related macular
degeneration in the untreated fellow eye. Case Rep Ophthalmol Med.
2018(8561895)2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wu Z and Sadda SR: Effects on the
contralateral eye after intravitreal bevacizumab and ranibizumab
injections: A case report. Ann Acad Med Singapore. 37:591–593.
2008.PubMed/NCBI
|
|
34
|
Peyman M, Peyman A, Lansingh VC, Orandi A
and Subrayan V: Intravitreal bevacizumab versus ranibizumab:
Effects on the vessels of the fellow non-treated eye. J Curr
Ophthalmol. 31:55–60. 2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Filip-Ciubotaru F, Manciuc C, Stoleriu G
and Foia L: NADPH oxidase: Structure and activation mecanisms
(Review). Note I. Rev Med Chir Soc Med Nat Iasi. 120:29–33.
2016.PubMed/NCBI
|
